In CRC, the combination of E2F1 and NCAPD3 promotes glycolysis, inhibits the tricarboxylic acid cycle, and participates in reprogramming glucose metabolism in CRC cells [52]. This evidence concerns the gene E2F1 and colorectal carcinoma.